Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to ...

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

While you're collecting healthy dividends, you'll also benefit from the price-to-earnings (P/E) ratio expanding when revenue ...

In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...

PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.

Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers ...

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...